RNA-Targeting CRISPR/CasRx system relieves disease symptoms in Huntington's disease models.
Lin Y, Li C, Chen Y, Gao J, Li J, Huang C, Liu Z, Wang W, Zheng X, Song X, Wu J, Wu J, Luo OJ, Tu Z, Li S, Li XJ, Lai L, Yan S.
Lin Y, et al. Among authors: li xj.
Mol Neurodegener. 2025 Jan 13;20(1):4. doi: 10.1186/s13024-024-00794-w.
Mol Neurodegener. 2025.
PMID: 39806441